Pirfenidone use in patients with idiopathic pulmonary fibrosis may be linked to a lower incidence of lung cancer. Learn more.

Kohen's team explored pirfenidone (PFD) for its antifibrotic activity, aiming to reduce scarring around GDDs without the ...

Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Pirfenidone (CAS 53179-13-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ...

Keep this leaflet with the medicine. You may need to read it again. Esbriet contains the active ingredient pirfenidone. Esbriet is used to treat Idiopathic Pulmonary Fibrosis (IPF). IPF is a ...

For treating pulmonary fibrosis, presently the pharmacological arsenal involves only two drugs, pirfenidone and nintedanib, which work to slow down the disease progression but do not completely ...